Gastroparesis during pegylated interferon therapy for chronic hepatitis C: Effects of mosapride

Gastroparesis during pegylated interferon therapy for chronic hepatitis C: Effects of mosapride - Effects of mosapride for interferon gastroparesis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003890

Enrollment

Registered

2010-07-09

Start date

2006-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

Mosapride group: pegylated (Peg) interferon (IFN) (Pegintron

Schering-Plough Co., Inc., NJ, USA) 60-100 microgram per week and 5 miri gram of mosapride citrate (Gasmotin

Dainippon Sumitomo Pharma Co., Inc., Tokyo, Japan) orally three times daily Control group: PegIFN 60-100 microgram per week with no mosapride citrate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: histologically confirmed chronic active hepatitis, presence of hepatitis C virus (HCV) RNA

Exclusion criteria

Exclusion criteria: presence of gastrointestinal disease and history of gastric surgery

Design outcomes

Primary

Measure	Time frame
total gastric T1/2, proximal gastric T1/2, distal gastric T1/2, and digestive symptoms scored at the time of gastric emptying scintigraphy	—

Countries

Japan

Contacts

Public ContactEtsushi Kawamura

Graduate School of Medicine, Osaka City University Dept. of nuclear medicine

etsushi-k@med.osaka-cu.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026